Why the study?
How should digoxin toxicity be managed, and what is the role of digoxin-specific antibody fragments?
How should digoxin toxicity be managed, and what is the role of digoxin-specific antibody fragments?
Digoxin-specific antibody fragments are a safe and effective treatment for severe digoxin toxicity, requiring post-treatment monitoring for rebound toxicity.
Recognize digoxin toxicity despite therapeutic levels to avert arrhythmias; leaves open standardized Fab fragment indications.
Digoxin toxicity can emerge during long-term therapy as well as after an overdose. It can occur even when the serum digoxin concentration is within the therapeutic range. Toxicity causes anorexia, nausea, vomiting and neurological symptoms. It can also trigger fatal arrhythmias. There is a range of indications for using digoxin-specific antibody fragments. The amount ingested and serum digoxin concentration help to determine the dose required, but are not essential. Digoxin-specific antibody fragments are safe and effective in severe toxicity. Monitoring should continue after treatment because of the small risk of rebound toxicity. Restarting therapy should take into account the indication for digoxin and any reasons why the concentration became toxic.
No takes yet. Share an insight, caveat, or question.
M. Pincus (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: